Verition Fund Management
APRE icon

Verition Fund Management’s Aprea Therapeutics APRE Stock Holding History

Verition Fund Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,005
Closed -$13K – 2120
2022
Q3 		$13K Hold
1,005
– – ﹤0.01% 2842
2022
Q2 		$15K Hold
1,005
– – ﹤0.01% 2237
2022
Q1 		$37K Sell
1,005
-1
-0.1% -$41 ﹤0.01% 2524
2021
Q4 		$58K Buy
1,006
+1
+0.1% +$88 ﹤0.01% 2396
2021
Q3 		$103K Buy
+1,005
New +$91.3K ﹤0.01% 1704

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's APRE Position: Q4 2022 in Review

Verition Fund Management sold out of Aprea Therapeutics (APRE) in Q4 2022, closing a stake of 1,005 shares — an estimated $13K sold.

Verition Fund Management first reported a position in APRE in Q3 2021 and held it in 5 quarters. The position peaked at $103K in Q3 2021. 24 funds tracked by Wall St. Rank hold APRE as of Q4 2022.

  • Verition Fund Management reported no remaining Aprea Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Verition Fund Management sold 1,005 Aprea Therapeutics shares in Q4 2022, an estimated $13K.
  • Verition Fund Management first reported a position in Aprea Therapeutics in Q3 2021 and held it in 5 quarters.
  • Verition Fund Management's Aprea Therapeutics position peaked at $103K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2022.

Based on Verition Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.